AbbVie Begins Construction of New API Manufacturing Plant in North Chicago
Tuesday, September 30, 2025
AbbVie has started building a new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois. The project marks a key step in expanding AbbVie's U.S. manufacturing network, capabilities, and production capacity.
The facility will strengthen AbbVie's chemical synthesis capabilities and allow the company to transfer API production for certain products from Europe and Asia to the U.S. This move will support domestic production of current and future neuroscience, immunology, and oncology medicines.
API manufacturing involves a complex, multi-step process to produce the active components that provide therapeutic effects in medicines. Once operational, the North Chicago plant will enhance AbbVie's ability to develop and supply these critical components.
AbbVie has a presence across all 50 states and Puerto Rico, employing 28,000 people in the U.S. The $195 million investment in North Chicago is expected to create new jobs and expand AbbVie's existing U.S. manufacturing footprint, which currently supports more than 6,000 jobs across 11 sites. The investment also reinforces AbbVie's long-term commitment to Illinois, where its headquarters is located and where over 11,000 employees work on developing and manufacturing innovative medicines for patients worldwide.
Source: prnewswire.com
